Chuangxin International Secures Nearly RMB 1 Billion Series B Funding to Accelerate Organoid Technology R&D and Commercialization

VCBeat has learned at the earliest opportunity,ACCURATE BIOTECHNOLOGY (Guangzhou) Co., Ltd. (“ACCURATE BIOTECHNOLOGY”) has officially announced the completion of its Series B financing round, raising nearly RMB 100 million.This Round of FinancingBy Guangdong Science & Technology Fund and Zhongshan Haochuang Fund under Toukong DonghaiCo-led investment to accelerate ACCURATE BIOTECHNOLOGY’s R&D translation and global commercialization of organoid technology, injecting strong innovative momentum into the biomedical sector.

ACCURATE BIOTECHNOLOGY, as a leading enterprise across the entire organoid industry chain, has built an integrated ecological platform covering the full lifecycle of organoids, leveraging its independently innovated core technology system.Focusing on three strategic pillars—precision medicine, new drug R&D, and intelligent manufacturing—the Company centers on the scaled application of organoid-based tumor therapy, regenerative medicine, and synthetic biology. By breaking through key industry bottlenecks, it drives the organoid sector toward a leapfrog development characterized by intelligence, standardization, and industrialization. Leveraging internationally leading technology platforms, multi-dimensional data intelligence systems, and deep synergy with clinical resources, ACCURATE BIOTECHNOLOGY continues to accelerate the global translation and implementation of its technological achievements. It provides systematic support for innovative breakthroughs in life sciences, leading the industry from technological exploration into a new phase of large-scale industrial application.

In April 2025, the U.S. FDA issued a new regulation,It explicitly proposes the phased elimination of animal experimentation models and recommends the use of human cell-based models, including organoids.This marks an accelerating shift in the global paradigm of life sciences research toward new model systems that “more closely resemble the human body.” As three-dimensional in vitro models that highly mimic the structure and function of human organs, organoids have become key tools for precision medicine and innovative drug development.

As a global pioneer in organoid technology, ACCURATE BIOTECHNOLOGY is redefining the core pathways of life science R&D through foundational technological innovations and the reconstruction of a full-chain ecosystem, providing breakthrough technical support for precision medicine, innovative drug development, and complex disease research.

Dr. Huang Min, Chairman and CEO of ACCURATE BIOTECHNOLOGY, stated: “We extend our sincere gratitude to Guangdong Science & Technology Venture Capital Fund, Toukong Donghai, and all other investors for their strong recognition and strategic support. Leveraging this round of financing as an opportunity, ACCURATE BIOTECHNOLOGY will adopt a three-dimensional drive of ‘technology platform + data intelligence + industrial applications’ to build a technological ecosystem covering the entire lifecycle of organoids. We will continue to intensify R&D in core technologies and product innovation, establish a product matrix in key sectors such as intelligent organoid devices and chips, and data intelligence systems, thereby promoting technological breakthroughs and industrial upgrading, with the commitment to becoming a global leader in the organoid industry.”

Galaxy Yueke Private Fund stated: “ACCURATE BIOTECHNOLOGY possesses leading organoid technology and an industrialization platform. Its technological achievements hold immense application value in cutting-edge fields such as precision medicine and new drug R&D, aligning with our investment philosophy of focusing on core technology sectors. We believe that ACCURATE BIOTECHNOLOGY will occupy a pivotal position amidst industry transformation.”

Toukong Donghai stated: “As the flagship platform under Shenzhen Capital Group dedicated to early- and mid-stage sci-tech innovation enterprises, we highly recognize the technological depth and growth potential of ACCURATE BIOTECHNOLOGY. This investment is not only a key component of our strategic layout in the biomedical sector but will also drive the high-quality development of the biomedical industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area.”

This Series B financing round not only represents deep recognition by the global capital market of ACCURATE BIOTECHNOLOGY’s technological foresight and commercial value, but also marks the dawn of a new era for organoid technology, characterized by scaled-up and industrialized development. Its strategic layout focuses on cutting-edge global fields, accelerating the widespread application of organoid technology in pharmaceutical R&D worldwide through cross-regional collaboration and multi-dimensional resource integration. This process will not only reshape the global value chain of the biopharmaceutical industry, but also address human health challenges through scientific innovation, driving precision medicine into a new phase of higher efficiency and broader coverage, thereby injecting sustained momentum into the advancement of global life sciences.